Sofosbuvir/velpatasvir/voxilaprevir for previous treatment failures with glecaprevir/pibrentasvir in chronic hepatitis C infection
B Pearlman, M Perrys, A Hinds - Official journal of the American …, 2019 - journals.lww.com
Objectives: Chronic hepatitis C-infected patients who do not respond to nonstructural 5A
inhibitor-containing regimens have few treatment options. It is unclear if patients who fail …
inhibitor-containing regimens have few treatment options. It is unclear if patients who fail …
SHARED: an international collaboration to unravel hepatitis C resistance
AYM Howe, F Ceccherini-Silberstein, J Dietz… - Viruses, 2021 - mdpi.com
The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion
Fluoxazolevir is an aryloxazole-based entry inhibitor of hepatitis C virus (HCV). We show
that fluoxazolevir inhibits fusion of HCV with hepatic cells by binding HCV envelope protein …
that fluoxazolevir inhibits fusion of HCV with hepatic cells by binding HCV envelope protein …
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in …
M Kjellin, H Kileng, D Akaberi… - Scandinavian journal …, 2019 - Taylor & Francis
Abstract Background: The NS5A resistance-associated substitution (RAS) Y93H is found
quite frequently (5–10%) at baseline in direct-acting antiviral agents (DAA) treatment-naïve …
quite frequently (5–10%) at baseline in direct-acting antiviral agents (DAA) treatment-naïve …
Sustained virological response with 16‐week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post‐transplant severe HCV recurrence in HIV
Direct‐acting antivirals (DAAs) demonstrated high efficacy and safety even in the post‐liver
transplant (LT) setting and in HIV‐infected patients, but data are very limited in the early post …
transplant (LT) setting and in HIV‐infected patients, but data are very limited in the early post …
Chronic hepatitis C: Epidemiology, viral resistance, and public health implications
H Kileng - 2019 - munin.uit.no
Chronic hepatitis C: Epidemiology, viral resistance, and public health implications Chronic
hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver disease. The …
hepatitis C virus (HCV) infection can progress to cirrhosis and end-stage liver disease. The …
[PDF][PDF] SHARED: An International Collaboration to Unravel Hepatitis C Resistance. Viruses 2021, 13, 1580
AY Howe, F Ceccherini-Silberstein, J Dietz, S Popping… - 2021 - pdfs.semanticscholar.org
The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …